Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Debt Repayments

Debt Repayments at other companies

Absci Corporation logo
Absci CorporationABSI
$460K-39.6%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$0—

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-28.6%
Enterprise value$1.22B-37.5%
P/S31×-5.9×

Profitability

See full
Gross margin3.5%—
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio5×+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Cash flows from financing activities
Proceeds from issuance of common shares, net of issuance costs—141,024
Equity incentive plans(278)4,293
Repayment of long-term debt and finance lease liabilities(4,459)(4,131)
Purchase of an intangible asset—(3,000)
Net cash provided by (used in) financing activities(4,737)138,186
Effect of exchange rate changes on cash, cash equivalents and restricted cash(3,019)14,088
Net change in cash, cash equivalents and restricted cash(197,101)(69,179)

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s debt repayments?
Recursion Pharmaceuticals, Inc. (RXRX) reported debt repayments of $2.25M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s debt repayments changed year-over-year?
Recursion Pharmaceuticals, Inc.'s debt repayments increased by 8.0% year-over-year, from $2.08M to $2.25M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s debt repayments?
Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s debt repayments has grown at a -9.9% compound annual growth rate (CAGR), from $12.8M to $8.43M.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Ask your AI about Recursion Pharmaceuticals, Inc.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude